Zaltrap and Capecitabine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zaltrap (ziv-aflibercept) and Capecitabine (capecitabine). Common drug interactions include neurotoxicity among females and cerebrovascular accident among males.

The phase IV clinical study analyzes what interactions people have when they take Zaltrap and Capecitabine. It is created by eHealthMe based on reports of 55 people who take the same drugs from the FDA, and is updated regularly.

What is Zaltrap?

Zaltrap has active ingredients of ziv-aflibercept. eHealthMe is studying from 1,432 Zaltrap users. Check the latest studies of Zaltrap.

What is Capecitabine?

Capecitabine has active ingredients of capecitabine. eHealthMe is studying from 59,495 Capecitabine users. Check the latest studies of Capecitabine.

On Jul, 28, 2026

55 people who take Zaltrap and Capecitabine together, and have interactions are studied.

Zaltrap and Capecitabine drug interactions.

What are the common drug interactions of Zaltrap and Capecitabine, by gender? *:

female:

Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Asthenia (weakness)
Hypersensitivity
Neutropenia (an abnormally low number of neutrophils)
Metastases to liver (cancer spreads to liver)
Metastatic neoplasm (spreadable cancer tumour)
Nausea (feeling of having an urge to vomit)
Diarrhoea
Muscle spasms (muscle contraction)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)

male:

Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Disease progression
Hypertension (high blood pressure)
Leukopenia (less number of white blood cells in blood)
Gastrointestinal toxicity (damage to digestive tract by any substance)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Bone marrow toxicity (decrease in cells responsible for providing immunity, carrying oxygen, and those responsible for normal blood clotting)
Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
Therapeutic response decreased (less preventive response)
Drug ineffective

What are the common drug interactions of Zaltrap and Capecitabine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Fistula (an abnormal connection or passageway between two)
Ileus (a painful obstruction of the ileum or other part of the intestine)
Nausea (feeling of having an urge to vomit)
Vomiting

50-59:

Disease progression
Diarrhoea
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Muscle spasms (muscle contraction)
Abdominal pain
Exposed bone in jaw
Metastases to lung (cancer spreads to lung)
Sepsis (a severe blood infection that can lead to organ failure and death)
Blood pressure increased

60+:

Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Asthenia (weakness)
Liver injury
Therapeutic response decreased (less preventive response)
Drug ineffective
Albuminuria (albumin is present in the urine)
Anaemia (lack of blood)
Exposed bone in jaw
Fatigue (feeling of tiredness)
Gingivitis (inflammation of gums)

What are the existing conditions these people have? *

Rectal Cancer (cancer of rectum): 13 people, 23.64%
High Blood Pressure: 9 people, 16.36%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 9 people, 16.36%
Rectal Cancer Metastatic (cancer of rectum spreads to other): 7 people, 12.73%
Metastatic Neoplasm (spreadable cancer tumour): 6 people, 10.91%
Metastases To Lung (cancer spreads to lung): 6 people, 10.91%
Metastases To Liver (cancer spreads to liver): 6 people, 10.91%
Large Intestine Perforation (hole in large intestine): 5 people, 9.09%
Colon Cancer: 3 people, 5.45%

* Approximation only. Some reports may have incomplete information.

Do you take Zaltrap and Capecitabine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously